High response rate with TopoTarget's BelCaP
Copenhagen, Denmark-based TopoTarget AS presented positive data from a study of its BelCaP anticancer drug cocktail (belinostat/carboplatin/paclitaxel) in ovarian cancer at the Biennial Ovarian Cancer Research Symposium, held in Seattle, USA.
The Phase II open-label, non-randomized multicenter trial tested the regimen containing the firm's histone deacetylase inhibitor, belinostat, as well as carboplatin and paclitaxel, in patients with relapsed epithelial ovarian cancer. 35 patients were included with an overall response rate of 43%, four continue on therapy, with three complete remissions and 12 partial remissions, as measured using the Response Evaluation Criteria in Solid Tumours scale.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze